Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
3099 results about "Luetic disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The topic Luetic Disease you are seeking is a synonym, or alternative name, or is closely related to the medical condition Syphilis – General. Syphilis is a very common infectious disease caused by the bacterium Treponema pallidum. Syphilis is generally transmitted through sexual contact.
Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Owner:FINCH THERAPEUTICS HLDG LLC
EGFR inhibitors and methods of treating disorders
The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
Owner:DANA FARBER CANCER INST INC
Methods for treating gastrointestinal disorders
InactiveUS20110097401A1Suitable for treatmentSalicyclic acid active ingredientsBiocideGastrointestinal disorderGastrointestinal tract
Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.
Owner:MERITAGE PHARMA INC
Perfused three-dimensional cell/tissue disease models
ActiveUS8318479B2Easy to primeBioreactor/fermenter combinationsBiological substance pretreatmentsLymphatic SpreadPathology diagnosis
A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.
Owner:MASSACHUSETTS INST OF TECH +1
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
ActiveUS20110033465A1Overcome technical difficultiesOrganic active ingredientsAntipyreticPeptide inhibitorPCSK9
The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.
Owner:MERCK SHARP & DOHME CORP
Combination vaccine
ActiveUS20160166678A1SsRNA viruses negative-senseSugar derivativesHemagglutininFamily Orthomyxoviridae
The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
Owner:CUREVAC SE
Anti-activin A antibodies and uses thereof
ActiveUS8309082B2No improvement in cachexiaReduce weightAntipyreticAnalgesicsAntibody fragmentsPolynucleotide
The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
Owner:AMGEN INC
Multiple virus resistance in plants
Owner:MONSANTO TECH LLC
Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
InactiveUS20110206646A1Ease and low morbidityAvoid contaminationBiocideMetabolism disorderProgenitorLymphatic vessel
Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and / or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.
Owner:LOREM VASCULAR PTE LTD
Quantification of adaptive immune cell genomes in a complex mixture of cells
Owner:ADAPTIVE BIOTECH +1
Anti-viral treatment and assay to screenfor Anti-viral agent
InactiveUS20130085133A1Improve palatabilityImprove stabilityBiocideSugar derivativesCytopathic effectAntiviral drug
The present disclosure relates to novel compounds of formulas (1) through (19) and to a method for treating humans infected with a virus including various respiratory viruses such as members of the Paramyxoviridae family (respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), measles virus, and mumps virus) with a compound of formulas (1) through (19). The present disclosure also relates to a cytopathic effect (CPE)-based assay that will assess virus-induced CPE for screening of compounds for treating viral diseases or inhibiting a virus.
Owner:SOUTHERN RES INST & IP
Compositions and methods for inhibiting gene expression of hepatitis B virus
Owner:ARROWHEAD PHARMA INC
Osteoclast inhibitors for joint conditions
ActiveUS9610300B2Improve bioavailabilityPhosphorous compound active ingredientsPill deliveryNitrogenAnesthesia
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
Owner:ANTECIP BIOVENTURES II
Fully human antibodies to BTLA
ActiveUS8563694B2High binding affinityImprove pharmacokineticsSenses disorderNervous disorderAntibodyLuetic disease
Owner:ER SQUIBB & SONS INC
Methods and compositions for treatment of neurological disorders
InactiveUS20110111014A1Reduce riskShorten the progressBiocideHeavy metal active ingredientsPediatricsNeurological disorder
Methods and compositions are provided for preventing and treating neurological disorders, in particular Parkinson's disease.
Owner:THE PARKINSONS INST +1
Methods and compositions for disease treatment using inhalation
InactiveUS20120077786A1Increasing subject 's convenienceGood treatment complianceBiocideOrganic active ingredientsPulmonary edemaLung cancer
Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.
Owner:MICRODOSE THERAPEUTX INC
Small molecule antagonists of the apelin receptor for the treatment of disease
InactiveUS20140005181A1BiocideOrganic chemistryTHC receptorErythropoietin-producing hepatocellular (Eph) receptor
Owner:SANFORD BURNHAM MEDICAL RES INST
Anti-cd40 antibodies and uses thereof
ActiveUS20140093497A1Reduce the frequency of occurrenceReduce severityOrganic active ingredientsMicroorganismsEpitopeTransplant rejection
The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
Owner:EMORY UNIVERSITY +1
Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
InactiveUS20110230520A1Superior vasodilating propertyBiocideOrganic chemistryPharmacologyLuetic disease
Nitrate derivatives of cilostazol are described. They have superior properties and clinical advantages compared to cilostazol in the treatment of vascular and metabolic diseases.
Owner:CARDIOLYNX
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
ActiveUS8216575B2Reduce neovascularizationImprove acuitySenses disorderPeptide/protein ingredientsChimerin ProteinsEndothelial NOS
Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.
Owner:CHENGDU KANGHONG BIOTECH
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
ActiveUS20140256742A1Avoids side-effectsReduce duplicationBiocideOrganic active ingredientsLysineLuetic disease
Owner:ORYZON GENOMICS SA
Means and methods for the prediction of treatment response of a cancer patient
ActiveUS20130330325A1Enhance their cancer-fighting capacityIncrease capacityMicrobiological testing/measurementDisease diagnosisSurgeryTreatment response
The present invention relates to the field of treatment efficacy prediction in patients with malignant diseases. More precisely, this invention relates to the prediction of the efficacy of a treatment in cancer patients, based on the precise quantification of several biological markers that are related to the innate and adaptive immune response of said patient against said cancer.
Owner:GRABE NIELS +3
Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy
ActiveUS20140242049A1Enhance luciferase activityMaximize the effectBiocideAntibody mimetics/scaffoldsSide effectCancer cell
A transformed T-cell for T-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the transfection of a gene for coding a chimera protein. The T-cell, to which the gene for coding the chimera protein is transected, may improve the therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction to induce the activation of T-cells. Also, the disclosure allows treatments that minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation.
Owner:NAT CANCER CENT
Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient
ActiveUS8754209B2Inhibitory activityOrganic chemistryDermatological disorderPTK InhibitorsTyrosine-kinase inhibitor
Owner:KOREA INST OF SCI & TECH +2
Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections
Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
Owner:RESPIVERT
Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to tnfr2
ActiveUS20120094934A1Modulate its functionOrganic active ingredientsPeptide/protein ingredientsPolynucleotideInhibitory effect
The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.
Owner:CURNA INC
Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
ActiveUS20110027270A1Reduce in quantityLower titerSsRNA viruses negative-senseVirus peptidesMonoclonal antibodyVirus diseases
Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.
Owner:MT SINAI SCHOOL OF MEDICINE
2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections
The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.
Owner:UNIV OF GEORGIA RES FOUND INC
Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
Owner:SEATTLE GENETICS INC
Chinese medicinal preparation for treating hypertension, hyperglycemia and hyperlipidemia
InactiveCN101972373AWhole nature and mild flavorFood safetyAnthropod material medical ingredientsMetabolism disorderAcute hyperglycaemiaMedicinal herbs
The invention discloses a Chinese medicinal preparation for treating hypertension, hyperglycemia and hyperlipidemia. A medicament is prepared from more than ten Chinese medicinal herbs such as kelp, yellowmouth dutchmanspipe root, safflower, earthworm, vine root and the like. The preparation has extremely remarkable treatment effects on diseases such as diabetes, the hypertension and the hyperlipidemia. When applied to a patient with two indexes exceeding standards, the preparation has good treatment effect and no side effect.
Owner:赵全会
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com